Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger, John H. Alexander, John J.V. McMurray, Renato D. Lópes, Elaine M. Hylek, Michael G. Hanna, Hussein R. Al‐Khalidi, Jack Ansell, Dan Atar, Álvaro Avezum, M. Cecilia Bahit, Rafael Díaz, J. Donald Easton, Justin A. Ezekowitz, Greg Flaker, David García, Margarida Geraldes, Bernard J. Gersh, Golitsyn Sp, Shinya Goto, Antonio G. Hermosillo, Stefan H. Hohnloser, John D. Horowitz, Puneet Mohan, Petr Janský, Basil S. Lewis, José López‐Sendón, Prem Pais, Alexander Parkhomenko, Freek W.A. Verheugt, Jun Zhu, Lars Wallentin

New England Journal of Medicine, 2011

Duke University, Duke Medical Center, Clinical Research Institute, University Medical Center, Bristol-Myers Squibb (United States), Lenox Hill Hospital, Oslo University Hospital, Instituto Dante Pazzanese de Cardiologia, Estudios Clínicos Latinoamérica, University of California, San Francisco, University of Alberta, University of Missouri Health System, University of New Mexico, Mayo Clinic in Arizona, Institute of Experimental Cardiology, Tokai University, Instituto Nacional de Cardiología, Goethe University Frankfurt, University of Adelaide, University Hospital in Motol, Carmel Medical Center, Hospital Universitario La Paz, St.John's Medical College Hospital, OLVG, Chinese Academy of Medical Sciences & Peking Union Medical College, Fu Wai Hospital, Uppsala University

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

8840

Citations

View on Google Scholar

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Abstract

Journal Details

Join JournalsHub

Welcome Back